PAM
DNLI icon

Panagora Asset Management’s Denali Therapeutics DNLI Stock Holding History

Panagora Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-29,726
Closed -$719K – 2711
2020
Q2 		$719K Hold
29,726
– – ﹤0.01% 1054
2020
Q1 		$521K Hold
29,726
– – ﹤0.01% 1100
2019
Q4 		$518K Hold
29,726
– – ﹤0.01% 1289
2019
Q3 		$455K Buy
+29,726
New +$568K ﹤0.01% 1319

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Panagora Asset Management's DNLI Position: Q3 2020 in Review

Panagora Asset Management sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 29,726 shares — an estimated $719K sold.

Panagora Asset Management first reported a position in DNLI in Q3 2019 and held it in 4 quarters. The position peaked at $719K in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • Panagora Asset Management reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Panagora Asset Management sold 29,726 Denali Therapeutics shares in Q3 2020, an estimated $719K.
  • Panagora Asset Management first reported a position in Denali Therapeutics in Q3 2019 and held it in 4 quarters.
  • Panagora Asset Management's Denali Therapeutics position peaked at $719K in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on Panagora Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.